Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | APEX1 | P27695 | 2/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL768162 | 1.00 | PNMT (0.56) | PNMTBLMMAPTRECQLTDP1 | |
| SCHEMBL31419997 | 1.00 | PNMT (0.56) | PNMTBLMMAPTRECQLTDP1 | |
| SCHEMBL3489554 | 1.00 | PNMT (0.56) | PNMTBLMMAPTRECQLTDP1 | |
| Hydrochloric Acid SCHEMBL4465387 | 0.98 | PNMT (0.54) | PNMTBLMMAPTRECQLTDP1 | |
| Hydrochloric Acid SCHEMBL2327859 | 0.98 | PNMT (0.54) | PNMTBLMMAPTRECQLTDP1 | |
| Hydrochloric Acid SCHEMBL4802312 | 0.98 | PNMT (0.54) | PNMTBLMMAPTRECQLTDP1 | |
| Hydrochloric Acid SCHEMBL31332749 | 0.98 | PNMT (0.54) | PNMTBLMMAPTRECQLTDP1 | |
| Bicarbonate SCHEMBL9515153 | 0.93 | KDM4E (0.51) | PNMTBLMMAPTRECQLTDP1 | |
| SCHEMBL10318241 | 0.85 | ADRB2 (0.44) | PNMTTAAR1ADRB2ADRB1ADRB3 | |
| SCHEMBL1154749 | 0.83 | ADRB3 (0.49) | ADRB2ADRB1ADRB3LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183276-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-15 | — | — | US | disclosed |
| US-RE49500-E1 | Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-25 | — | — | US | disclosed |
| EP-3943489-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | Vertex Pharmaceuticals Incorporated (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3608315-B1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | VERTEX PHARMA (US) | 2021-08-11 | — | — | EP | disclosed |
| US-RE48266-E1 | Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-10-20 | — | — | US | disclosed |
| EP-3608315-A1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Vertex Pharmaceuticals Incorporated (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3305776-B1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | VERTEX PHARMA (US) | 2019-09-25 | — | — | EP | disclosed |
| US-RE47318-E1 | Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3305776-A1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Vertex Pharmaceuticals Incorporated (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2799434-B1 | Pyrrole compounds as inhibitors of ERK protein kinases and pharmaceutical compositions containing these compounds | VERTEX PHARMA (US) | 2017-08-02 | — | — | EP | disclosed |
| US-6114582-A | DECYCLIZATION TO FORM A CHEMICAL INTERMEDIATE FOR PRODUCING AN ANTI-OBESITY AGENT AND ANTIDIABETIC AGENT | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-05 | — | — | US | disclosed |
| EP-0654534-B1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEM (JP) | 2000-03-01 | — | — | EP | disclosed |
| EP-0939134-A1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-01 | — | — | EP | disclosed |
| EP-0924194-A2 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| EP-0924193-A1 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| US-5811293-A | CULTURE PRODUCT AS CHEMICAL INTERMEDIATE FOR ANTI-OBESITY AGENT | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| EP-0825189-A1 | 1,4-BENZODIOXIN DERIVATIVES | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1998-02-25 | — | — | EP | disclosed |
| US-5629200-A | MICROORGANISM | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1997-05-13 | — | — | US | disclosed |
| EP-0654534-A2 | Processes for producing optically active 2-amino-1-phenylethanol derivatives | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-24 | — | — | EP | disclosed |
| EP-0303545-A2 | Process for the preparation of phenylethanolaminotetralines | ELF SANOFI (FR) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183276-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | MAPK1, MAP3K1, MAP3K20 | PNMT 1460/4885BLM 3855/4885MAPT 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.